ApicHope's subsidiary obtains registration certificate for Methanesulfonic acid new strychnine injection
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, ApicHope announced that its wholly-owned subsidiary Guangzhou Lianrui Pharmaceutical Co., Ltd. recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for Methanesulfonate Neostigmine Injection. The indications for Methanesulfonate Neostigmine Injection are: anticholinesterase drug. It is used to antagonize the residual muscle relaxant effects of non-depolarizing muscle relaxants at the end of surgery, and for conditions such as myasthenia gravis, postoperative functional intestinal distension, and urinary retention
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments